【摘要】 目的通过观察血清α-L-岩藻糖昔酶（AFU）活性水平在原发性肝细胞癌（HCC）患者与肝硬化、肝炎及其他恶性肿瘤患者中的变化，评价其在HCC诊断中的价值。方法对44例HCC、18例肝硬化、36例肝炎和30例其他恶性肿瘤患者测定血清AFU活性水平。部分HCC患者曾经接受经导管肝动脉化疗栓塞术（TAE）。结果对照组平均血清AFU活性水平为150．39±35．34nKat／L，HCC组280．11±148．15nKat／L，肝硬化组、肝炎组及其他肿瘤组分别为248．89±68．82、196．67±79.61、168.93±49．89nKat／L。HCC组与对照组及肝炎组、其他肿瘤组之间存在明显差别，但与肝硬化组有部分重叠。结论AFU可作为肿瘤标志物用于诊断HCC与AFP及超声等联合参照应用。更多还原

【Abstract】 Purpose To assess the value of serum α-L-fucosidase (AFU) as a marker for hep- atocellular carcinoma(HCC). Materials and Methods The activity of AFU was measured in patientswith HCC,liver cirrhosis,hepatitis or other kinds of malignant tumors and in control subjects. ResultsThe mean serum AFU activity was significantly higher in 44 patients with HCC (280.11±148. 15nKat/L) than in 36 patients with hepatitis and 30 patients with other malignant tumor (196. 67±79. 61nKat/L and 168. 93±49. 89nKat/L respectively). The overlap between HCC and cirrhosis wasobserved. Conclusions AFU can be used as a tumor marker in the detection of HCC. However, theoverlap between HCC and cirrhosis limits its value in the diagnosis of HCC.[更多还原